Hefei Lifeon Pharmaceutical Co., Ltd.

SZSE:003020 Stock Report

Market Cap: CN¥3.9b

Hefei Lifeon Pharmaceutical Past Earnings Performance

Past criteria checks 3/6

Hefei Lifeon Pharmaceutical has been growing earnings at an average annual rate of 12.8%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 0.7% per year. Hefei Lifeon Pharmaceutical's return on equity is 9.2%, and it has net margins of 11.6%.

Key information

12.8%

Earnings growth rate

5.9%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate0.7%
Return on equity9.2%
Net Margin11.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Why Hefei Lifeon Pharmaceutical's (SZSE:003020) Shaky Earnings Are Just The Beginning Of Its Problems

Nov 05
Why Hefei Lifeon Pharmaceutical's (SZSE:003020) Shaky Earnings Are Just The Beginning Of Its Problems

Hefei Lifeon Pharmaceutical's (SZSE:003020) Profits May Not Reveal Underlying Issues

Apr 29
Hefei Lifeon Pharmaceutical's (SZSE:003020) Profits May Not Reveal Underlying Issues

Recent updates

Why Hefei Lifeon Pharmaceutical's (SZSE:003020) Shaky Earnings Are Just The Beginning Of Its Problems

Nov 05
Why Hefei Lifeon Pharmaceutical's (SZSE:003020) Shaky Earnings Are Just The Beginning Of Its Problems

Hefei Lifeon Pharmaceutical (SZSE:003020) Has A Somewhat Strained Balance Sheet

Sep 30
Hefei Lifeon Pharmaceutical (SZSE:003020) Has A Somewhat Strained Balance Sheet

Hefei Lifeon Pharmaceutical (SZSE:003020) Has Announced A Dividend Of CN¥0.50

May 23
Hefei Lifeon Pharmaceutical (SZSE:003020) Has Announced A Dividend Of CN¥0.50

Investors Still Aren't Entirely Convinced By Hefei Lifeon Pharmaceutical Co., Ltd.'s (SZSE:003020) Earnings Despite 25% Price Jump

May 22
Investors Still Aren't Entirely Convinced By Hefei Lifeon Pharmaceutical Co., Ltd.'s (SZSE:003020) Earnings Despite 25% Price Jump

Hefei Lifeon Pharmaceutical's (SZSE:003020) Profits May Not Reveal Underlying Issues

Apr 29
Hefei Lifeon Pharmaceutical's (SZSE:003020) Profits May Not Reveal Underlying Issues

Revenue & Expenses Breakdown

How Hefei Lifeon Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:003020 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,50117478079
30 Jun 241,40217371579
31 Mar 241,42319164096
31 Dec 231,90122766385
30 Sep 232,21021064481
30 Jun 232,61824270585
31 Mar 232,76322870073
01 Jan 232,57920967674
30 Sep 222,50321767475
30 Jun 222,42918767568
31 Mar 222,35317867167
31 Dec 212,27317265066
30 Sep 212,18316160952
30 Jun 212,07615355654
31 Mar 211,99114849451
31 Dec 201,89413543343
30 Sep 201,80912740847
30 Jun 201,75812038445
31 Mar 201,71110937336
31 Dec 191,65010536337
31 Dec 181,4259229524
31 Dec 171,1677714418
31 Dec 161,028679312
31 Dec 14962541070
31 Dec 13878471080

Quality Earnings: 003020 has high quality earnings.

Growing Profit Margin: 003020's current net profit margins (11.6%) are higher than last year (9.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 003020's earnings have grown by 12.8% per year over the past 5 years.

Accelerating Growth: 003020's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 003020 had negative earnings growth (-17%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).


Return on Equity

High ROE: 003020's Return on Equity (9.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies